Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

LAE118 is in IND-enabling studies and IND is expected to be ... with global leading pharmaceutical companies to accelerate clinical development and commercialization of our drug candidate assets. We ...

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers; Advancing novel EGFR-targeted ant ...

Vericel's FDA-approved regenerative medicine products and robust pipeline signal strong growth potential, with zero debt and ...

Navigating the stock market requires a keen understanding of current economic indicators, sectoral shifts, and emerging ...

(NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) ...